BioSmart Co (038460) Fair Value & Analysis
Technology · KR · Market cap 70.9B KRW
Fair value as of: Jul 7, 2026
From 14 valuation models · updated yesterday
Fair value updated Jul 7, 2026 — revised from 9,019 KRW to 7,129 KRW (−21.0%) since Jul 6, 2026. Share price −12.4% over the past month.
Price vs Fair Value (12 months)
12‑month range 2,403 KRW – 6,458 KRW · fair‑value band 5,347 KRW – 8,911 KRW · the 2,635 KRW price screens below the 7,129 KRW fair value. As of Jul 7, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
BioSmart Co (038460) currently trades at 2,635 KRW, while our model-based Fair Value estimate is 7,129 KRW — implying the stock looks roughly 170.6% undervalued today. We read business quality at 33/100 (below-average quality), in the Technology sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.
Over the trailing twelve months, BioSmart Co generated revenue of 333B KRW at a net margin of 0.7%. Revenue grew 94.2% year over year. Net debt stands at 41.8B KRW. Fundamentals as of Jul 7, 2026
Our scenario range runs from 5,347 KRW (bear case) to 8,911 KRW (bull case); at 2,635 KRW, the current price sits below that range. The share trades about 62% below its 52-week high and 2% above its 52-week low, currently below its 200-day average. For context, the median of 10 Technology peers we cover trades at 111% fair-value upside — at 171%, 038460 screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 7, 2026. TTM = trailing twelve months.
About the company
BioSmart Co.,Ltd. manufactures and sells magnetic stripe (MS) cards in South Korea. The company's magnetic stripe cards include credit cards, smart cards, traffic cards, securities cards, etc. It also sells card equipment, such as traffic card issuing machinery, smart card issuing machinery, credit card issuing machinery, etc.; provides card issuing services comprising MS card and IC chip personalization, and photo-transferring; and develops software programs related to credit card issuing. The company was formerly known as KBC Corporation and changed its name to BioSmart Co.,Ltd. in March 2007. BioSmart Co.,Ltd. was founded in 1971 and is headquartered in Seoul, South Korea.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
BioSmart Co reported revenue of 483B KRW in FY2025 versus 189B KRW in FY2021, a compound +26.4%/yr. Reported net income was 9.0B KRW in FY2025, compounding +59.5%/yr from FY2021.
Is 038460 fairly valued? → Check now
Similar stocks
10 more Electronic Equipment & Parts stocks, each showing price versus our Fair Value estimate (as of Jul 7, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Amotech Co 052710 | 23,850 KRW | 15,450 KRW | -35% |
| Partron Co 091700 | 6,510 KRW | 9,123 KRW | +40% |
| KHVATEC Co 060720 | 11,350 KRW | 34,386 KRW | +203% |
| Namuga Co 190510 | 13,120 KRW | 27,621 KRW | +111% |
| MNTech Co 095500 | 7,100 KRW | 10,882 KRW | +53% |
| Ajinextek Co 059120 | 5,550 KRW | 1,121 KRW | -80% |
| e-LITECOM CO., Ltd 041520 | 8,110 KRW | 13,553 KRW | +67% |
| CoAsia Corporation 045970 | 2,965 KRW | 11,855 KRW | +300% |
| Inzi Display Co 037330 | 1,080 KRW | 3,600 KRW | +233% |
| Display Tech Co 066670 | 2,705 KRW | 10,723 KRW | +296% |
Explore undervalued stocks
More undervalued Technology stocks →
Frequently asked questions
Is BioSmart Co (038460) undervalued?
What is the fair value of 038460?
What is the quality score of 038460?
What is the revenue of BioSmart Co (038460)?
What is the net profit margin of 038460?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.